Chronic myeloid leukaemia (CML) is a type of blood cancer that is characterized by the abnormal growth of myeloid cells in the bone marrow. Imatinib is a tyrosine kinase inhibitor that has been used as a standard treatment for CML, but the development of drug resistance has limited its efficacy. The combination treatment of Imatinib with flavonoids such as Naringin has shown promising results in terms of overcoming drug resistance and enhancing the therapeutic efficacy of Imatinib. The generation of reactive oxygen species such as LDH, MDA, and catalase in K562 cells treated with Imatinib and Naringin in combination suggests that this therapy may have potential as a treatment for CML. In the present study, LDH assay, MDA estimation, and catalase activity are determined to know ROS production in the cell line culture. The results of the LDH assay showed that the combination treatment of Imatinib and Naringin significantly reduced the release of LDH compared to the control group, The results of the MDA assay showed that the combination treatment of Imatinib and Naringin significantly reduced the levels of MDA compared to the control group. This suggests that the combination therapy has a protective effect on the cell membranes and the results of the catalase assay showed that the combination treatment of Imatinib and Naringin significantly increased the levels of catalase compared to the control group. The combination treatment of Imatinib and Naringin has been shown to yield promising results in terms of the generation of ROS such as LDH, MDA, and catalase in K562 cell lines.